ArticleOpen veterinary journal2025
Silymarin alleviates diclofenac-induced hepatotoxicity in male Wistar rats: Histopathological investigation.
Article in Open veterinary journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: One of the primary concerns of the pharmaceutical industry is the potential for liver damage caused by drugs. Diclofenac is a member of the family of nonsteroidall anti-inflammatory medications, which are known for their anti-inflammatory, antipyretic, and analgesic effects. Although it is commonly prescribed, liver damage is one of the primary risks associated with this medication. Therefore, it is necessary to use a prospective therapeutic medication that can counteract the cytotoxic impact of diclofenac. Humans have utilized natural items as a means of obtaining sustenance, maintaining their health, and treating a wide variety of illnesses. Antioxidant, anti-inflammatory, and liver-protective properties are associated with Aim: This study aimed to evaluate the possible hepatoprotective effect of silymarin against diclofenac-induced liver injury. Methods: Forty Wistar rats were used in the current investigation and grouped randomly into four equal groups. The first group (G1) was kept as a control group. G2 received intraperitoneal injections of diclofenac (50 mg/kg. BW/day) for 5 days. G3 received oral silymarin for 5 days (200 mg/kg BW/day) dissolved in distal water. G4 received diclofenac plus silymarin with the same previously mentioned doses for 5 days. The animals were collected and subjected to histopathological examination. Results: The diclofenac-treated group showed several pathological changes within the hepatic parenchyma, including diffuse coagulative and hydropic degenerations with general disorganization of the hepatic cords, severe dilatation and congestion of the central vein and portal blood vessels, severe sinusoidal dilatation and congestions accompanied with severe pressure atrophy of the hepatic cords, and severe inflammatory cell infiltrations. Meanwhile, the diclofenac plus silymarin-treated group showed a significant good effect, where silymarin ameliorated almost all histopathological lesions induced after diclofenac treatment as mitigating the degenerative changes of hepatocytes, minimizing inflammatory cell infiltrations, and normal organized hepatic rays with normal sinusoids in between were distinguished. Conclusion: Silymarin has a significant hepatoprotective effect against diclofenac-induced hepatotoxicity through neutralization of all histopathological injuries.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.